Why Do GLP-1 Drugs Cause Hair Loss, and Does It Grow Back?

The short answer: Hair loss on GLP-1 drugs is real and it is on the FDA labels. The Wegovy label reports hair loss in 3.3% of adults on the 2.4 mg dose versus 1% on placebo, and it states plainly that those reactions were associated with weight reduction. The pattern fits telogen effluvium, a temporary shedding that follows a physical stress by about three months. In almost all cases the hair grows back once weight and nutrition stabilize.

How common is hair loss on GLP-1 drugs?

The weight-loss labels carry real numbers. The diabetes labels do not.

The Wegovy (semaglutide) prescribing information lists hair loss among the adverse reactions reported in 5% or more of patients. In the adult weight-reduction trial pool, hair loss was reported by 3.3% of patients on Wegovy 2.4 mg and 1% of patients on placebo. In the higher 7.2 mg trials, the figures were 5.8% on 7.2 mg, 3.3% on 2.4 mg, and 1.0% on placebo.

The Zepbound (tirzepatide) prescribing information is similar. Hair loss was reported by 5% of patients on 5 mg, 4% on 10 mg, and 5% on 15 mg, against 1% on placebo.

The diabetes versions are different. The Ozempic and Rybelsus label and the Mounjaro label list alopecia only under Postmarketing Experience. That section covers voluntary reports from a population of uncertain size, so no frequency can be estimated. Hair loss did not reach the clinical-trial tables for either diabetes product. For the wider picture of what these drugs do, see our guide to GLP-1 side effects.

Why does the shedding happen?

Both labels point at the weight loss, not the molecule. The Wegovy label states that hair loss adverse reactions "were associated with weight reduction," and the Zepbound label uses the same wording.

The mechanism dermatologists describe is telogen effluvium. According to StatPearls on NCBI Bookshelf, a physical stressor pushes roughly 70% of growing (anagen) hairs prematurely into the resting (telogen) phase. Those hairs then shed together a few months later. The listed triggers include crash dieting, low protein intake, iron deficiency, surgery, and acute illness. Rapid weight loss sits squarely on that list.

A retrospective study of weight-loss telogen effluvium in Annals of Dermatology looked at 140 patients. The mean weight loss was 15.21% of body weight at a mean rate of 3.54 kg per month. The authors found women and older adults especially vulnerable, even when their weight loss was not more severe.

Two patterns in the label data support the weight-loss explanation. First, the rate rises with the dose that produces more weight loss: 5.8% on Wegovy 7.2 mg versus 3.3% on 2.4 mg. Second, the reports skew heavily female. On Wegovy 2.4 mg the split was 4% of women and 0.9% of men. On Zepbound it was 7.1% of women and 0.5% of men. The same rapid-loss physiology that strips lean tissue is at work here, which is why muscle loss on GLP-1 drugs and hair shedding show up in the same people.

Is the drug itself to blame?

Nobody has proven a direct effect on the follicle. The available evidence is signal detection, not causation.

A 2026 disproportionality analysis in the Journal of Cosmetic Dermatology mined FDA Adverse Event Reporting System data from 2016 to 2025 across seven GLP-1 receptor agonists. Semaglutide had the most reports (697). A statistical signal appeared for semaglutide in 2024 (reporting odds ratio 1.55, 95% CI 1.35 to 1.77). Tirzepatide produced the strongest signal, in 2025 (ROR 2.08, 95% CI 1.86 to 2.32, 324 cases). Semaglutide and tirzepatide were the only two agents in the class to generate significant signals.

One detail is suggestive: 25% of semaglutide reports documented positive dechallenge (the hair loss improved after stopping) and 18% documented positive rechallenge (it returned after restarting). The authors still called for further monitoring rather than declaring a causal link. FAERS reports are voluntary and unverified, and media attention inflates reporting.

A 2025 systematic review in Cureus found only five eligible studies covering 2,905 patients. Two studies reported hair loss as an adverse event, while three reported improvement and regrowth in patients already being treated for alopecia. For a drug-specific walkthrough, see the Ozempic hair loss breakdown at ozempic.md.

When does the shedding start?

Not in the first week. StatPearls puts the average delay between the trigger and visible shedding at three months, with a range of one to six months. The stress has usually passed by the time the hair falls.

Weight-loss surgery gives a useful parallel. A case report and review in Cureus describes two patterns after bariatric surgery. Acute hair loss appears within the first three months and is typically telogen effluvium from the surgical and metabolic stress. Chronic hair loss appears around six months out and is more often tied to a nutritional deficiency.

On a GLP-1, shedding usually follows the steepest stretch of weight loss by a few months.

Does the hair grow back?

Yes, in the usual case. Telogen effluvium is a non-scarring alopecia, which means the follicles survive. StatPearls describes it as self-limited: once the stressor is removed or a deficiency is corrected, recovery happens on its own.

The timeline requires patience. StatPearls states that acute telogen effluvium shedding lasts less than six months and often much shorter. Regrowth "may take up to 6 months to restart and even longer for the growth to be appreciated by the patient." A year from trigger to normal hair is ordinary, not a sign of failure.

Stopping the drug is rarely the answer the labels support. In the Wegovy 7.2 mg trials, one hair loss event led to permanent discontinuation, one to a temporary interruption, and five to a dose reduction. In the Zepbound trials, no treated patient discontinued because of hair loss. If you are weighing a pause anyway, read what happens when you stop taking GLP-1 drugs first.

Do iron, zinc or protein matter?

They matter, but do not assume a deficiency is present. The Cureus bariatric review notes that nutritional deficiencies occur in roughly half of bariatric surgery patients and can involve iron, protein, zinc, copper, selenium, and several vitamins. Those deficiencies are strongly linked to the later, chronic form of hair loss. GLP-1 drugs differ from bypass surgery: they suppress appetite rather than block absorption. The risk comes from eating too little, not from a rerouted gut.

The lab picture is also less clear-cut than popular advice suggests. A case-control study of 90 women with chronic telogen effluvium and 90 controls, published in the Journal of Cosmetic Dermatology, found significantly lower zinc levels in patients. It found no difference in hemoglobin, ferritin, vitamin B12, thyroid function tests, vitamin D, copper, or biotin. The authors concluded that nutritional deficiencies are not as common in telogen effluvium as often assumed, and that a careful history and exam should come before supplements.

The practical reading: ask a clinician for labs rather than stacking supplements on guesswork. High-dose biotin also interferes with common lab assays.

What should you actually do?

• Protect protein intake. Low protein intake is a listed trigger, and appetite suppression makes undereating easy.
• Watch the rate, not just the total. The labels tie hair loss to the magnitude of weight reduction.
• Talk to the prescriber before quitting. Dose reduction was the most common response in the trials, and almost nobody stopped.
• Ask for labs if shedding runs past six months. Persistent loss is outside the usual acute telogen effluvium window.
• Get a dermatologist involved for patchy or scarring loss. Diffuse thinning is telogen effluvium. Bald patches, a widening part, or a scarred scalp point elsewhere.

The bottom line

GLP-1 hair loss is on the label, it is uncommon, and it is far more likely a consequence of losing weight fast than a direct attack on the follicle. The label rates run from 3.3% to 5.8% on semaglutide and 4% to 5% on tirzepatide, against about 1% on placebo. Because telogen effluvium is non-scarring and self-limited, the hair comes back for nearly everyone, usually starting within about six months of the trigger passing. Slower weight loss and adequate protein are the levers you actually control.

Last updated: September 2026. This article is for informational purposes only and does not constitute medical advice. Talk to your prescriber or a dermatologist before changing a GLP-1 dose or starting supplements for hair loss.